Your browser is no longer supported. Please, upgrade your browser.
ALNY Alnylam Pharmaceuticals, Inc. daily Stock Chart
ALNY [NASD]
Alnylam Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-8.27 Insider Own0.50% Shs Outstand109.34M Perf Week5.46%
Market Cap8.95B Forward P/E- EPS next Y-7.29 Insider Trans-17.24% Shs Float109.34M Perf Month-4.22%
Income-858.10M PEG- EPS next Q-2.05 Inst Own97.00% Short Float5.76% Perf Quarter8.64%
Sales101.10M P/S88.55 EPS this Y-39.80% Inst Trans-0.03% Short Ratio8.82 Perf Half Y-0.23%
Book/sh16.18 P/B5.06 EPS next Y9.30% ROA-43.00% Target Price113.39 Perf Year-1.24%
Cash/sh17.62 P/C4.65 EPS next 5Y46.09% ROE-56.40% 52W Range60.27 - 96.08 Perf YTD12.30%
Dividend- P/FCF- EPS past 5Y-39.20% ROI-59.70% 52W High-14.78% Beta2.35
Dividend %- Quick Ratio6.20 Sales past 5Y9.70% Gross Margin90.60% 52W Low35.86% ATR2.80
Employees1065 Current Ratio6.30 Sales Q/Q49.50% Oper. Margin- RSI (14)55.03 Volatility2.66% 3.66%
OptionableYes Debt/Eq0.02 EPS Q/Q-24.20% Profit Margin- Rel Volume0.69 Prev Close81.67
ShortableYes LT Debt/Eq0.02 EarningsNov 05 BMO Payout- Avg Volume713.79K Price81.88
Recom2.10 SMA202.59% SMA500.73% SMA2002.80% Volume495,147 Change0.26%
May-23-19Resumed Goldman Neutral $80
Apr-12-19Initiated Evercore ISI Outperform
Mar-06-19Upgrade Evercore ISI In-line → Outperform
Mar-05-19Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-23-19Initiated UBS Neutral $87
Oct-01-18Initiated Cantor Fitzgerald Overweight $135
Aug-13-18Reiterated Stifel Buy $125 → $123
Aug-07-18Upgrade Stifel Hold → Buy $95 → $125
May-04-18Reiterated Stifel Hold $107 → $95
Mar-28-18Initiated Evercore ISI In-line
Mar-26-18Reiterated JMP Securities Mkt Outperform $169 → $207
Feb-16-18Reiterated B. Riley FBR, Inc. Buy $205 → $200
Jan-08-18Reiterated B. Riley FBR, Inc. Buy $220 → $205
Nov-09-17Upgrade JP Morgan Neutral → Overweight
Nov-08-17Reiterated Barclays Overweight $127 → $158
Nov-08-17Reiterated B. Riley FBR, Inc. Buy $240 → $220
Nov-03-17Reiterated Needham Buy $125 → $152
Nov-02-17Reiterated B. Riley FBR, Inc. Buy $150 → $240
Oct-30-17Initiated FBR & Co. Buy $150
Oct-02-17Upgrade Goldman Neutral → Buy
Oct-16-19 09:15AM  Earnings Season Makes Good First Impression Zacks
Oct-15-19 06:00AM  Alnylams Distinguished Chemist Mano Manoharan Receives Lifetime Achievement Award from the Oligonucleotide Therapeutics Society Business Wire
Oct-10-19 07:30AM  Alnylam Announces Filing for Marketing Authorization of ONPATTRO® (patisiran) in Brazil for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy Business Wire
Oct-01-19 06:31AM  With eyes on IPO, muscular dystrophy startup names new CEO American City Business Journals -7.35%
Sep-27-19 07:27AM  If You Had Bought Alnylam Pharmaceuticals (NASDAQ:ALNY) Shares Three Years Ago You'd Have Made 14% Simply Wall St.
Sep-26-19 12:05PM  Medicines Company's Inclisiran Succeeds in Pivotal Studies Zacks
08:30AM  Alnylam to Webcast Presentation at 2019 Cantor Global Healthcare Conference Business Wire
Sep-23-19 12:08PM  Regeneron/Sanofi Gets Positive CHMP Opinion for Dupixent Zacks
Sep-19-19 11:02AM  Alnylam Focuses on Pipeline Development Amid Competition Zacks
Sep-17-19 10:27AM  Alnylam Begins Phase III Study on Onpattro for New Indication Zacks
Sep-16-19 07:30AM  Alnylam Pharmaceuticals Announces Initiation of APOLLO-B Phase 3 Study of Patisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy Business Wire
Sep-13-19 09:00AM  What Makes Alnylam (ALNY) a New Buy Stock Zacks
07:30AM  Alnylam Presents New Evidence Demonstrating Significant Association of V122I, a Highly Prevalent, Pathogenic Transthyretin (TTR) Mutation, with Clinical Diagnosis of Polyneuropathy Business Wire
Sep-11-19 08:30AM  1,000 Alnylam Employees Across the Globe Volunteer at 5th Annual Community Service Day Business Wire
Sep-10-19 05:30AM  Alnylam Presents New Clinical Results for Givosiran at the 2019 International Congress on Porphyrins and Porphyrias Business Wire
Sep-09-19 09:31AM  3 Biotech Stocks That Could Soar This Week Motley Fool
Sep-06-19 03:06PM  Why Amgen's Spending Billions to Buy This 1 Drug; Plus Heart Disease Has a New Enemy Motley Fool
07:30AM  Alnylam to Host Sixth Annual RNAi Roundtable Webcast Series Business Wire
Sep-05-19 09:31AM  Why Is Alnylam (ALNY) Up 2.3% Since Last Earnings Report? Zacks
Sep-04-19 10:17AM  Biotech vet George Scangos steers new company toward nine-figure IPO American City Business Journals
Sep-03-19 04:15PM  This Biotech Stock Is Looking To Leapfrog Its Rivals And Buy Point Investor's Business Daily
01:47PM  This Biotech Stock Is Looking To Leapfrog Its Rivals And Buy Point Investor's Business Daily
Sep-02-19 03:13PM  The Week Ahead In Biotech: Cardiology, Analyst Conferences In The Spotlight Benzinga
Aug-30-19 08:00AM  Alnylam to Webcast Presentation at 17th Annual Morgan Stanley Global Healthcare Conference Business Wire
Aug-28-19 03:16PM  Is Arrowhead Pharmaceuticals Inc (ARWR)s Recently Published U.S. Patent Application A Blockbuster? Insider Monkey
Aug-27-19 11:19AM  Medicines Company's Inclisiran Succeeds in Pivotal Study Zacks
Aug-26-19 05:43PM  Heres Why The Medicines Company Shares Jumped 13.8% Today Motley Fool
Aug-15-19 09:00AM  BioBoyScouts Online Biotech Valuation Calculators Help Small Investors See Value in Arrowhead Pharmaceuticals (ARWR) Insider Monkey
08:28AM  Regeneron Gets FDA Nod for Eylea Injection Prefilled Syringe Zacks
Aug-14-19 09:21AM  Biotech Stock Roundup: Amgen's Enbrel Patent Win, AMRN's Setback & More Zacks
08:00AM  Alnylam to Report New Clinical Results for Givosiran at the 2019 International Congress on Porphyrins and Porphyrias Business Wire
Aug-13-19 07:30AM  Ironwood Pharmaceuticals and Alnylam Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylams Givosiran in Acute Hepatic Porphyria (AHP) Business Wire
07:30AM  Alnylam Pharmaceuticals and Ironwood Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylams Givosiran in Acute Hepatic Porphyria (AHP) Business Wire
Aug-12-19 04:13PM  Alnylam Adds on Sales, Looks to Pipeline for Further Growth Motley Fool
11:07AM  Edited Transcript of ALNY earnings conference call or presentation 6-Aug-19 12:00pm GMT Thomson Reuters StreetEvents
Aug-07-19 08:13AM  Alnylam's (ALNY) Q2 Earnings and Revenues Miss Estimates Zacks +8.23%
Aug-06-19 03:23PM  Alnylam Pharmaceuticals Inc (ALNY) Q2 2019 Earnings Call Transcript Motley Fool
01:09PM  Regeneron (REGN) Q2 Earnings Top Estimates, Eylea Sales Solid Zacks
08:55AM  Alnylam Pharmaceuticals (ALNY) Reports Q2 Loss, Lags Revenue Estimates Zacks
07:30AM  Alnylam Pharmaceuticals Reports Second Quarter 2019 Financial Results and Highlights Recent Period Activity Business Wire
07:22AM  The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering Benzinga
Aug-05-19 04:00PM  Alnylam Announces U.S. Food and Drug Administration (FDA) Granted Priority Review of the Givosiran New Drug Application (NDA) for the Treatment of Acute Hepatic Porphyria Business Wire
Aug-02-19 11:12AM  bluebird's (BLUE) Loss Wider Than Expected, Revenues Beat Zacks
10:28AM  Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q2 Zacks
Aug-01-19 09:54AM  Amgen (AMGN) Catches Eye: Stock Jumps 5.7% Zacks
Jul-30-19 10:38AM  Earnings Preview: Alnylam Pharmaceuticals (ALNY) Q2 Earnings Expected to Decline Zacks
Jul-29-19 10:08AM  A Look At The Fair Value Of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Simply Wall St.
Jul-26-19 10:38AM  Alkermes (ALKS) Earnings and Sales Beat Estimates in Q2 Zacks
Jul-25-19 11:25AM  Medicines Company (MDCO) Q2 Earnings Top, Inclisiran in View Zacks
Jul-24-19 01:54PM  Alexion (ALXN) Q2 Earnings Beat Estimates, Guidance Raised Zacks
Jul-23-19 04:00PM  Alnylam to Webcast Conference Call Discussing Second Quarter 2019 Financial Results Business Wire
07:00AM  Alnylam Launches ONPATTRO® (patisiran) for the Treatment of Polyneuropathy in hATTR Amyloidosis, the First-Ever RNAi Therapeutic Approved in Canada CNW Group
Jul-19-19 09:41AM  Horizon's NDA for Procysbi New Dosage Form Accepted by FDA Zacks
Jul-16-19 07:00AM  Alnylam and 23andMe Collaborate on +MyFamily Program to Increase Awareness of TTR-Related Hereditary Amyloidosis Business Wire
Jul-11-19 09:05AM  Horizon Therapeutics Files BLA to FDA for Eye Disease Drug Zacks
08:58AM  Adverum (ADVM) Jumps: Stock Rises 5.1% Zacks
08:30AM  Alnylam Pharmaceuticals Announces Transition of Chief Financial Officer Business Wire
Jul-10-19 05:53PM  Mirati Inks Deal with Novartis to Evaluate Tumor Candidate Zacks
05:51PM  Kadmon Initiates Dosing in Study for Systemic Sclerosis Drug Zacks
Jul-05-19 12:04PM  Catalyst Pharma Focuses on Firdapse Launch & Label Expansion Zacks
Jul-04-19 09:00AM  Alnylam (ALNY) Upgraded to Strong Buy: What Does It Mean for the Stock? Zacks
Jul-02-19 04:01PM  Arbutus Sells Part of its ONPATTRO (patisiran) Royalty Interest to OMERS GlobeNewswire
02:57PM  Alnylam Submits MAA in Europe for RNAi Therapeutic Givosiran Zacks
Jul-01-19 11:00AM  Regeneron/Sanofi's Dupixent Gets Positive CHMP Recommendation Zacks
07:00AM  Alnylam Submits Marketing Authorization Application to the European Medicines Agency for Givosiran for the Treatment of Acute Hepatic Porphyria Business Wire
Jun-27-19 07:39AM  Regeneron & Sanofi Get FDA Nod for Dupixent Label Expansion Zacks
Jun-25-19 08:00AM  Alnylam Presents New Data for RNAi Therapeutic Onpattro Zacks
Jun-24-19 07:00AM  Alnylam Presents New ONPATTRO® (patisiran) Results at the 2019 Peripheral Nerve Society Annual Meeting Business Wire
Jun-21-19 07:00AM  Alnylam Announces Progress with RNAi Therapeutics Platform, Including Oral Route of Administration and CNS and Ocular Delivery Business Wire
Jun-19-19 08:09PM  Heres What Hedge Funds Think About Alnylam Pharmaceuticals, Inc. (ALNY) Insider Monkey
Jun-18-19 09:58AM  Alnylam Completes Enrollment in Phase III Study of Lumasiran Zacks
08:00AM  Alnylam Announces Approval in Japan of ONPATTRO® for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy Business Wire
Jun-17-19 09:12AM  Regeneron (REGN) Presents Positive Data on Lymphoma Candidate Zacks
07:00AM  Alnylam Completes Enrollment for ILLUMINATE-A Phase 3 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 (PH1) Business Wire
Jun-14-19 02:50PM  Why Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Is A Financially Healthy Company Simply Wall St.
Jun-13-19 12:03PM  Boston-area biopharm firm has big plans in Philadelphia American City Business Journals
08:00AM  Alnylam to Report New Clinical Results for ONPATTRO® (patisiran) at Peripheral Nerve Society (PNS) Annual Meeting and the 5th Congress of the European Academy of Neurology (EAN) Business Wire
Jun-06-19 03:28PM  Alnylam Completes Rolling NDA Submission to FDA for Givosiran Zacks
Jun-05-19 07:00AM  Alnylam Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration (FDA) for Givosiran for the Treatment of Acute Hepatic Porphyria Business Wire
Jun-03-19 04:48PM  Alnylam Initiates Phase I Study on Hypertension Candidate Zacks
May-31-19 09:31AM  Why Is Alnylam (ALNY) Down 16.8% Since Last Earnings Report? Zacks
07:00AM  Alnylam Doses First Patient in Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension Business Wire
May-30-19 04:00PM  Alnylam to Webcast Presentations at Upcoming June Investor Conferences Business Wire
May-29-19 10:52AM  BioMarin Announces Data on Hemophilia Candidate, Shares Fall Zacks
08:00AM  Alnylam Announces New Leadership Appointments Business Wire
May-20-19 12:04PM  Credit Suisse Absolutely Is Right to Double Down on Pfizer Stock InvestorPlace
May-09-19 07:46AM  These 3 revolutionary genomics companies are changing lives for patients and investors MarketWatch
07:00AM  Alnylam to Webcast Presentation at Bank of America Merrill Lynch Health Care Conference 2019 Business Wire
May-08-19 08:03AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
May-07-19 08:21PM  Can Pfizer Leap Over the Competition With This Potential Blockbuster? Motley Fool
May-06-19 04:14PM  How Dow Jones' Pfizer Could Take On New Drugs From 2 Biotech Stocks Investor's Business Daily
10:04AM  Alnylam Pharmaceuticals Continues Onpattro Launch With More to Come Motley Fool
May-03-19 03:23PM  Edited Transcript of ALNY earnings conference call or presentation 1-May-19 12:30pm GMT Thomson Reuters StreetEvents -6.36%
01:49PM  Alnylam Pharmaceuticals Put Buyers Take Profits During Slide Schaeffer's Investment Research
May-02-19 06:43PM  Eaton Vance Worldwide Health Sciences Fund Buys 5 New Stocks GuruFocus.com
04:57PM  Regeneron (REGN) to Report Q1 Earnings: What's in Store? Zacks
10:00AM  Alnylam (ALNY) Reports Narrower-Than-Expected Loss in Q1 Zacks
09:16AM  Can Alnylam Pharmaceuticals Stock Start Climbing Again? Motley Fool
May-01-19 04:20PM  Alnylam Pharmaceuticals Inc (ALNY) Q1 2019 Earnings Call Transcript Motley Fool -7.06%
01:16PM  Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates Zacks
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. It provides ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. The company's development programs include Vutrisiran, an investigational RNAi therapeutic targeting transthyretin that is in Phase III trials for the treatment of transthyretin-mediated amyloidosis; Givosiran that is in Phase III trials to treat acute hepatic porphyrias; and Lumasiran, an investigational RNAi therapeutic, which is in Phase III clinical trials for glycolate oxidase to treat primary hyperoxaluria type 1. It is also developing Inclisiran, an investigational RNAi therapeutic targeting proprotein convertase subtilisin/kexin type 9 that is in Phase III clinical trials for the treatment of hypercholesterolemia; and Fitusiran, an investigational RNAi therapeutic that is in Phase III clinical trials for treating hemophilia A and B with or without inhibitors. In addition, the company engages in the development of Cemdisiran for complement-mediated diseases; ALN-AAT02 to treat alpha-1 anti-trypsin deficiency-associated liver disease; ALN-HBV02 for treating chronic hepatitis B virus infection; and other earlier-stage programs. Alnylam Pharmaceuticals, Inc. has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Ionis Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MARAGANORE JOHNChief Executive OfficerOct 14Option Exercise16.4349,456812,562239,449Oct 16 04:06 PM
MARAGANORE JOHNChief Executive OfficerOct 14Sale79.4549,4563,929,210189,993Oct 16 04:06 PM
MARAGANORE JOHNChief Executive OfficerMay 15Option Exercise16.4349,457812,579239,450May 17 04:07 PM
MARAGANORE JOHNChief Executive OfficerMay 15Sale70.0049,4573,461,990189,993May 17 04:07 PM
SHARP PHILIP ADirectorApr 15Option Exercise22.0915,000331,350250,633Apr 17 04:05 PM
SHARP PHILIP ADirectorApr 15Sale88.2315,0001,323,442235,633Apr 17 04:05 PM
MARAGANORE JOHNChief Executive OfficerNov 21Option Exercise21.3598,6362,105,879249,933Nov 26 04:11 PM